Biological variation of glycohemoglobin.

Glycohemoglobin (GHb) is a measure of long-term mean glycemia that predicts risks for the development and/or progression of diabetic complications in patients with type 1 and type 2 diabetes (1)(2). Several reports have suggested, however, that although the within-subject variation in GHb unrelated to glycemia is minimal, there is substantial between-subject variation in GHb, e.g., “low glycators” and “high glycators” (3)(4)(5). These reports have suggested that because of this large between-subject variation, GHb may not be useful for diabetes screening or diagnosis and that when GHb is used for routine management of patients with diabetes, different patients may require very different GHb target values to achieve the same overall glycemic status. We therefore examined the biological variation of GHb and fasting plasma glucose (FPG) in nondiabetic individuals. Individuals without diabetes (n = 48) participated in a study of an artificial sweetener that has no effect on GHb or plasma glucose concentrations [Submission to Food and Drug Administration. McNeil Specialty Products Company food additive petition 7A3987 (Sucralose), 1987–1997]. Because the study was designed to detect minimal changes in plasma glucose concentrations, all participants were men to avoid the effects of cyclic hormonal changes on insulin (and therefore, plasma glucose) concentrations. At the prestudy screening, all individuals were healthy on the basis of a medical history, physical examination, and electrocardiography results; results of hematology and blood chemistry studies, urine examination, and measures of blood …

[1]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[2]  P. Colman,et al.  Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Australian Diabetes Society, the Royal College of Pathologists of Australasia and the Australasian Association of Clinical Biochemists [consensus development , 1997, The Medical journal of Australia.

[3]  M. Dattani,et al.  An investigation into the lability of the bioactivity of human growth hormone using the ESTA bioassay. , 1996, Hormone research.

[4]  T. Kawarabayashi,et al.  Alteration of Plasma Ghrelin Levels Associated With the Blood Pressure in Pregnancy , 2002, Hypertension.

[5]  D. Goldstein,et al.  Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. , 2002, Diabetes care.

[6]  D. Simon,et al.  Epidemiological features of glycated haemoglobin A1c-distribution in a healthy population , 1989, Diabetologia.

[7]  Watts Nb.  Reproducibility (precision) in alternate site testing. A clinician's perspective. , 1995 .

[8]  G. Duvel.  The study group. , 1980 .

[9]  K. Kangawa,et al.  Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor , 2001, Trends in Endocrinology & Metabolism.

[10]  B. Keevil,et al.  Biological Variation of Glycated Hemoglobin: Implications for diabetes screening and monitoring , 1998, Diabetes Care.

[11]  C G Fraser,et al.  Generation and application of data on biological variation in clinical chemistry. , 1989, Critical reviews in clinical laboratory sciences.

[12]  F. Pi-Sunyer,et al.  Insulin, unlike food intake, does not suppress ghrelin in human subjects. , 2002, The Journal of clinical endocrinology and metabolism.

[13]  M. Rauh,et al.  Stability of salivary steroids: the influences of storage, food and dental care , 2001, Steroids.

[14]  W. Bablok,et al.  Application of statistical procedures in analytical instrument testing , 1985, The Journal of automatic chemistry.

[15]  M. Nakazato,et al.  Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. , 2000, Biochemical and biophysical research communications.

[16]  C. Jackson,et al.  Unexplained variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia , 1990, Diabetologia.

[17]  N. Wareham,et al.  Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk) , 2001, BMJ : British Medical Journal.

[18]  T. Hunter,et al.  Effect of duration and temperature of storage on serum analyte stability: examination of 14 selected radioimmunoassay procedures. , 1982, Clinical chemistry.

[19]  P. Phillips,et al.  Components of total measurement error for hemoglobin A(1c) determination. , 2001, Clinical chemistry.

[20]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[21]  W. Cefalu,et al.  Glycohemoglobin measured by automated affinity HPLC correlates with both short-term and long-term antecedent glycemia. , 1994, Clinical chemistry.

[22]  A. Avignon,et al.  Nonfasting Plasma Glucose is a Better Marker of Diabetic Control Than Fasting Plasma Glucose in Type 2 Diabetes , 1997, Diabetes Care.

[23]  R Smith,et al.  PubMed Central: creating an Aladdin's cave of ideas , 2001, BMJ : British Medical Journal.

[24]  M. Papotti,et al.  Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[25]  F. Casanueva,et al.  Ghrelin: a step forward in the understanding of somatotroph cell function and growth regulation. , 2000, European journal of endocrinology.

[26]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[27]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[28]  U. Janssens,et al.  Lower cardiac troponin T and I results in heparin-plasma than in serum. , 2000, Clinical chemistry.

[29]  K. Maurer,et al.  Third national health and nutrition examination survey , 1985 .

[30]  P. Hudson,et al.  Differences in Rates of Glycation (Glycation Index) May Significantly Affect Individual Hba1c Results in Type 1 Diabetes , 1999, Annals of clinical biochemistry.

[31]  M. Nakazato,et al.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. , 2002, The Journal of clinical endocrinology and metabolism.

[32]  J. Dötsch,et al.  Variability of Leptin Values Measured from Different Sample Matrices , 2001, Hormone Research in Paediatrics.

[33]  James M. Dabbs,et al.  Salivary testosterone measurements: Collecting, storing, and mailing saliva samples , 1991, Physiology & Behavior.

[34]  D. Singer,et al.  Tracking of glycated hemoglobin in the original cohort of the Framingham Heart Study. , 1996, Journal of clinical epidemiology.

[35]  Mogens Lytken Larsen,et al.  A Comparison of Analytical Goals for Haemoglobin A1c Assays Derived Using Different Strategies , 1991, Annals of clinical biochemistry.

[36]  N. Watts.  Reproducibility (precision) in alternate site testing. A clinician's perspective. , 1995, Archives of pathology & laboratory medicine.

[37]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[38]  H. Katus,et al.  Troponin T and I assays show decreased concentrations in heparin plasma compared with serum: lower recoveries in early than in late phases of myocardial injury. , 2000, Clinical chemistry.